

## SIDDHARTH KAUL, M.D., PhD

CLINICAL RESEARCH PROFESSIONALS

17295 Chesterfield Airport Road, Chesterfield, Missouri 63005 ☎ 636-220-1200 ■ 314-667-3331 fax

---

### EDUCATION

1999-2005	Ph.D-Neurotoxicology	Iowa State University of Science and Technology, Ames, IA
1992-1998	M.B.B.S-Bachelor of Medicine and Surgery	Jawahar Medical Foundation A.C.P.M Medical College, Maharashtra, India

### TRAINING

2009-2012	Residency-Neurology	Southern Illinois University of Medicine, Springfield, IL
2008-2009	Residency-Internal Medicine	Southern Illinois University of Medicine, Springfield, IL

### CERTIFICATION AND LICENSURE

Missouri	2012009717	Physician and Surgeon
----------	------------	-----------------------

### PROFESSIONAL EXPERIENCE

Current	Principal Investigator	Clinical Research Professionals, Chesterfield, Mo
2012-Present	Neurologist	DePaul Health Center, SSM Neurosciences Institute, Bridgeton, Mo
2011-2012	Express Care Physician	Midwest Emergency Department Services (MEDS), Springfield, IL
2004-2005	Teaching Assistant	Iowa State University, Ames, IA

### PROFESSIONAL ORGANIZATIONS/MEMBERSHIPS

Member of the American Headache Society  
Medecins Sans Frontieres (MSF/Doctors Without Borders)  
The Michael J. Fox Foundation for Parkinson's Research  
American Academy of Neurology

### PROFESSIONAL APPOINTMENTS

2014-Present	Medical Director-Stroke Service Line	St. Mary's Hospital, SSM Neurosciences, St. Louis, MO
--------------	--------------------------------------	---

### PRESENTATIONS

Seminal Google chat on SSM health website-Duration 60 minutes. Topic-"Migraine headaches-pathophysiology And management." Q & A live with email and Facebook questions from patients around the country.

[www.ssmhealth.com/live](http://www.ssmhealth.com/live)

Fox 2 News Appearance-"Using BOTOX to fight migraines" November 11<sup>th</sup> 2014-AM Show.

<http://kplr11.com/2014/09/22/what-you-need-to-know-about-migraine-headache-attacks/>

KPLR 11 News Appearance-"Migraine treatment and management" September 22, 2014-AM show with 2 of my migraine patients who were treated with Botox therapy. They were interviewed along with me on TV regarding The changes we had affected in their lives. <http://kplr11.com/2014/09/22/what-you-need-to-know-about-migraine-headache-attacks/>

## PUBLICATIONS

### Text Books:

Handbook of Experimental Neurology: Methods and Techniques in Animal Research. **Chapter 24:** Animal Models of Parkinson's disease. *Kanthsamy A.G and Kaul S. Edited by: Turgut Tatlisumak and Marc Fisher.* Accepted for Publication at Cambridge Press (August 2006-538pp Hardback) ISBN-13:9780521838146 | ISBN-10: 0521838142.

### Peer Reviewed Publications:

1. **Kaul S, Elble RJ.** Performance on the Pentagon drawing test in the Mini Mental State Examination is an early predictor of memory decline in Parkinson's disease patients. *Movement Disorders.* Mov Disord. 2014 Mar;29(3):427-8.doi: 10.1002/mds.25807.Epub 2014 Jan 21.
2. **Kaul S, Anantharam V, Kanthsamy A and Kanthsamy AG.** Wild-type alpha-synuclein interacts with pro-apoptotic proteins PKCdelta and BAD to protect dopaminergic neuronal cells against MPP+-induced apoptotic cell death. *Brain Research Mol Brain Res.* 2005 Sept 13; 139(1):137-52.
3. **Kaul S, Anantharam V, Yang Y, Choi CJ, Kanthsamy A and Kanthsamy AG.** Tyrosine phosphorylation regulates the proteolytic activation of protein kinase C delta in dopaminergic neuronal cells. *Journal of Biological Chemistry* 2005 Aug 5; 280(31):28721-30. Epub 2005 Jun 16.
4. **Kaul S, Kanthsamy A, Kitazawa M, Anantharam V and Kanthsamy AG.** Caspase-3 dependent proteolytic activation of protein kinase C delta mediates and regulates 1-methyl-4-phenylpyridinium (MPP+) –induced apoptotic cell death in dopaminergic cells: relevance to oxidative stress in dopaminergic degeneration. *Eur J Neurosci.* 2003 Sep; 18(6):1387-401.
5. **Yang Y, Kaul S, Zhang D, Anantharam V, Kanthsamy AG.** Suppression of caspase-3-dependent proteolytic activation of protein kinase C delta is regulated by small interfering RNA prevents MPP+-induced dopaminergic degeneration. *Mol Cell Neurosci.* 2004 Mar; 25(3):406-21.
6. **Kanthsamy AG, Kitazawa M, Kaul S, Yang Y, Lahiri DK, Anantharam V and Kanthsamy A.** Proteolytic activation of proapoptotic kinase PKCdelta is regulated by over expression of Bcl-2: implications for oxidative stress and environmental factors in Parkinson's disease. *Ann N Y Acad Sci.* 2003 Dec; 1010:683-6.
7. **Anantharam V, Kitazawa M, Wagner J, Kaul S, Kanthsamy AG.** Caspase-3-dependent proteolytic cleavage of protein kinase C delta is essential for oxidative stress-mediated dopaminergic cell death after exposure to methylcyclopentadienyl manganese tricarbonyl. *J Neurosci.* 2002 Mar 1; 22(5):1738-51.
8. **Kanthsamy AG, Anantharam V, Zhang D, Lathoumycandane C, Jin H, Kaul S, Kanthsamy A.** A novel peptide inhibitor targeted to caspase-3 cleavage site of a proapoptotic kinase protein kinase C delta (PKCdelta) protects against dopaminergic neuronal degeneration in Parkinson's disease models. *Free Radic Biol Med.* 2006 Nov 15; 41(10):1578-89. Epub 2006 Aug 25.PMID:17045926.
9. **Anantharam V, Kaul S, Song C, Kanthsamy A, Kanthsamy AG.** Pharmacological Inhibition of neuronal NADPH oxidase protects against 1-methyl-4-phenylpyridinium (MPP+)-induced oxidative stress and apoptosis in mesencephalic dopaminergic neuronal cells. *Neurotoxicology.* 2007 Sep;28(5):988-97. Epub 2007 Aug 25.

